MX2013008225A - Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. - Google Patents
Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.Info
- Publication number
- MX2013008225A MX2013008225A MX2013008225A MX2013008225A MX2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- opioid agonist
- oxycodone
- compositions
- sequestered antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención pertenece a una composición farmacéutica que comprende una pluralidad de perlas multi-capa que tienen una capa de oxicodona y una subunidad secuestrante que comprende una naltrexona y un agente de bloqueo, en particular las composiciones farmacéuticas comprenden un mayor nivel de naltrexona, y composiciones y métodos de uso, tal como en la prevención del abuso de un agente terapéutico. Las composiciones de la presente invención poseen también un prolongado Tmax para liberación de oxicodona y un perfil de liberación de oxicodona más uniforme con el paso del tiempo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438882P | 2011-02-02 | 2011-02-02 | |
| PCT/IB2012/050348 WO2012104752A1 (en) | 2011-02-02 | 2012-01-25 | Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013008225A true MX2013008225A (es) | 2013-08-12 |
Family
ID=45607315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013008225A MX2013008225A (es) | 2011-02-02 | 2012-01-25 | Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140141090A1 (es) |
| EP (1) | EP2670400A1 (es) |
| JP (3) | JP2014504630A (es) |
| KR (4) | KR20180027641A (es) |
| CN (1) | CN103415285A (es) |
| AU (3) | AU2012213056A1 (es) |
| BR (1) | BR112013019431A2 (es) |
| CA (1) | CA2824835A1 (es) |
| IL (1) | IL227770A0 (es) |
| MX (1) | MX2013008225A (es) |
| RU (1) | RU2013136350A (es) |
| SG (1) | SG191872A1 (es) |
| WO (1) | WO2012104752A1 (es) |
| ZA (1) | ZA201305108B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229705B1 (en) | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| US20120076865A1 (en) | 2010-03-24 | 2012-03-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| AU2018347991A1 (en) * | 2017-10-09 | 2020-05-07 | Rhodes Pharmaceuticals L.P. | Pharmaceutical resinate compositions and methods of making and using thereof |
| KR20210094513A (ko) * | 2018-11-19 | 2021-07-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 알코올-내성 약물 제형 |
| CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| KR20230071228A (ko) | 2021-11-16 | 2023-05-23 | 김명진 | 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치 |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| HU229705B1 (en) | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
| CN2423892Y (zh) * | 2000-04-30 | 2001-03-21 | 尹为民 | 分隔式药物胶囊 |
| ES2275868T3 (es) | 2001-05-11 | 2007-06-16 | Endo Pharmaceuticals Inc. | Forma de dosificacion de opioide para impedir el consumo abusivo. |
| ATE431738T1 (de) * | 2001-08-06 | 2009-06-15 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| HUE033015T2 (en) | 2004-05-04 | 2017-11-28 | Innophos Inc | Directly compressible tricalcium phosphate |
| CN101677963B (zh) | 2006-06-19 | 2012-05-30 | 奥尔制药公司 | 药物组合物 |
| CA2665726C (en) * | 2006-10-11 | 2016-04-19 | Alpharma, Inc. | Pharmaceutical compositions |
| US20090196890A1 (en) * | 2007-12-17 | 2009-08-06 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| CN101461809A (zh) * | 2007-12-18 | 2009-06-24 | 重庆药友制药有限责任公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
| KR20160017668A (ko) * | 2010-10-26 | 2016-02-16 | 알파마 파머슈티컬스 엘엘씨 | 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 |
-
2012
- 2012-01-25 JP JP2013552292A patent/JP2014504630A/ja not_active Withdrawn
- 2012-01-25 KR KR1020187006298A patent/KR20180027641A/ko active Application Filing
- 2012-01-25 SG SG2013052188A patent/SG191872A1/en unknown
- 2012-01-25 AU AU2012213056A patent/AU2012213056A1/en not_active Abandoned
- 2012-01-25 KR KR1020197002897A patent/KR20190014577A/ko not_active Application Discontinuation
- 2012-01-25 KR KR1020137023085A patent/KR20130124551A/ko not_active Application Discontinuation
- 2012-01-25 EP EP12704131.7A patent/EP2670400A1/en not_active Withdrawn
- 2012-01-25 KR KR1020167005412A patent/KR20160031038A/ko active Application Filing
- 2012-01-25 BR BR112013019431-6A patent/BR112013019431A2/pt not_active IP Right Cessation
- 2012-01-25 CN CN2012800076033A patent/CN103415285A/zh active Pending
- 2012-01-25 CA CA2824835A patent/CA2824835A1/en not_active Abandoned
- 2012-01-25 MX MX2013008225A patent/MX2013008225A/es unknown
- 2012-01-25 RU RU2013136350/15A patent/RU2013136350A/ru not_active Application Discontinuation
- 2012-01-25 US US13/982,890 patent/US20140141090A1/en not_active Abandoned
- 2012-01-25 WO PCT/IB2012/050348 patent/WO2012104752A1/en active Application Filing
-
2013
- 2013-07-08 ZA ZA2013/05108A patent/ZA201305108B/en unknown
- 2013-08-01 IL IL227770A patent/IL227770A0/en unknown
-
2016
- 2016-02-04 AU AU2016200708A patent/AU2016200708A1/en not_active Abandoned
- 2016-12-07 JP JP2016237476A patent/JP2017081942A/ja not_active Withdrawn
-
2017
- 2017-07-07 AU AU2017204639A patent/AU2017204639A1/en not_active Abandoned
-
2018
- 2018-03-07 JP JP2018040441A patent/JP2018109059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012213056A1 (en) | 2013-07-25 |
| EP2670400A1 (en) | 2013-12-11 |
| KR20180027641A (ko) | 2018-03-14 |
| KR20160031038A (ko) | 2016-03-21 |
| JP2014504630A (ja) | 2014-02-24 |
| JP2018109059A (ja) | 2018-07-12 |
| ZA201305108B (en) | 2014-09-25 |
| IL227770A0 (en) | 2013-09-30 |
| SG191872A1 (en) | 2013-08-30 |
| CA2824835A1 (en) | 2012-08-09 |
| AU2016200708A1 (en) | 2016-02-25 |
| BR112013019431A2 (pt) | 2020-10-27 |
| CN103415285A (zh) | 2013-11-27 |
| WO2012104752A1 (en) | 2012-08-09 |
| JP2017081942A (ja) | 2017-05-18 |
| KR20130124551A (ko) | 2013-11-14 |
| RU2013136350A (ru) | 2015-03-27 |
| KR20190014577A (ko) | 2019-02-12 |
| US20140141090A1 (en) | 2014-05-22 |
| AU2017204639A1 (en) | 2017-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013008225A (es) | Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. | |
| HK1200741A1 (en) | Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist | |
| IL228506A (en) | Opioid receptor ligands and pharmacy preparations containing them | |
| TWI561933B (en) | Resist underlayer film forming composition containing silicone having nitrogen-containing ring | |
| HK1193568A1 (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
| SI2619212T1 (sl) | Analogi buprenorfina kot agonisti in/ali antagonisti opioidnih receptorjev | |
| SI2552920T1 (sl) | Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah | |
| BRPI0919711A2 (pt) | composições farmacêuticas com liberação atenuada de opióides fenólicos | |
| MX2015000114A (es) | Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada. | |
| WO2012032209A3 (es) | Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora. | |
| MX365242B (es) | El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. | |
| BR112013016862A2 (pt) | combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson | |
| MX348933B (es) | Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. | |
| WO2009117669A3 (en) | Treatment with opioid antagonists and mtor inhibitors | |
| IL215813A0 (en) | Pariticulate pharmaceutical composition with an opioid and an opioid antagonist | |
| ZA201309359B (en) | Compositions for sequential administration of opioid receptor agonists | |
| MX2016008406A (es) | Preparacion farmaceutica combinada que comprende el bloqueante del receptor de la angiotensina ii y el inhibidor de la hmg-coa reductasa. | |
| EP3876938A4 (en) | COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS | |
| PT2802311T (pt) | Composição farmacêutica sublingual contendo um agente anti-histamínico e método para a sua preparação | |
| EP2793888A4 (en) | METHOD FOR TREATING AND PREVENTING OPIOID-INDUCED CREATION WITH ORAL COMPOUNDS FROM METHYL NALTREXONE | |
| AP2012006607A0 (en) | New combination between 4-ä3-ÄCIS-hexahydrocyclopenta[C]pyrrol-2(1H)-YL]propoxyübenzamide and an NMDA receptor antagonist and pharmaceutical compositions containing it | |
| HK1247105A1 (zh) | Mu類鴉片受體拮抗劑與類鴉片藥劑的組合劑型 | |
| EP2548893A4 (en) | DOUBLE ANTAGONIST FOR TNF-ALPHA AND IL-21 FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES | |
| TR201803744T4 (tr) | Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler. | |
| EP2307394A4 (en) | NOVEL COMPOUNDS, CORRESPONDING ISOMER OR CORRESPONDING PHARMACEUTICALLY ACCEPTABLE SALTS AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |